Systemic administration of local anesthetic agents to relieve neuropathic pain

Challapalli, Vidya; Tremont‐Lukats, Ivo W.; McNicol, Ewan D; Lau, Joseph; Carr, Daniel B.

doi:10.1002/14651858.cd003345.pub2

Cited by 148 publications

(91 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analgesia provided by IV lignocaine was similar to dihydroergotamine, but not as effective as chlorpromazine (Bell et al, 1990 Level II) and in one trial no better than placebo (Reutens et al, 1991 Level II Both lignocaine and mexiletine were more effective than placebo in treating chronic neuropathic pain, however there was no difference in efficacy or adverse effects when compared with carbamazepine, amantadine, or morphine (Challapalli et al, 2005 Level I).There was strong evidence of benefit for use of membrane stabilisers in pain due to peripheral nerve trauma (Kalso et al, 1998 Level I). Stump pain but not phantom pain was reduced by IV lignocaine (Wu et al, 2002 Level II).…”

Section: Membrane Stabilisersmentioning

confidence: 98%

Safety of opioid patch initiation in Australian residential aged care

Gadzhanova

Roughead

Pont

2015

Medical Journal of Australia

View full text Add to dashboard Cite

Objective: To explore opioid use by aged care facility residents before and after initiation of transdermal opioid patches. Design: A cross‐sectional cohort study, analysing pharmacy data on individual patient supply between 1 July 2008 and 30 September 2013. Setting: Sixty residential aged care facilities in New South Wales. Participants: Residents receiving an initial opioid patch during the study period. Main outcome measure: The proportion of residents who were opioid‐naive in the 4 weeks prior to patch initiation was determined. In addition, the patch strength at initiation and the daily dose of transdermal patches and of additional opioids 1 month after initiation were determined. Results: An opioid patch was initiated in 596 of 5297 residents (11.3%: 2.6% fentanyl, 8.7% buprenorphine) in the 60 residential aged care facilities. The mean age at initiation was 87 years, and 74% of the recipients were women. The proportion of recipients who were opioid‐naive before patch initiation was 34% for fentanyl and 49% for buprenorphine. Most were initiated at the lowest available patch strength, and the dose was up‐titrated after initiation. Around 15% of fentanyl users and 10% of buprenorphine users needed additional regular opioids after patch initiation. Conclusions: The results suggest some inappropriate initiation of opioid patches in Australian residential aged care facilities. Contrary to best practice, a third of residents initiated on fentanyl patches were opioid‐naive in the 4 weeks before initiation.

show abstract

Section: Membrane Stabilisersmentioning

confidence: 98%

Safety of opioid patch initiation in Australian residential aged care

Gadzhanova

Roughead

Pont

2015

Medical Journal of Australia

View full text Add to dashboard Cite

show abstract

“…A major advantage with IVLT is that appropriate use in adults is not associated with a significant side-effect profile [7,127,128]. In adults, a 100 mg bolus followed by an infusion at 1 mg/ min, which approximates to 1mg/kg/h, produces a plasma level of just over 1 μg/ml in normal individuals with no co-morbidities [129].…”

Section: Safety Of Ivlt For Pain Managementmentioning

confidence: 99%

A Review of Intravenous Lidocaine Infusion Therapy for Paediatric Acute and Chronic Pain Management

Lauder¹

2017

Pain Relief - From Analgesics to Alternative Therapies

View full text Add to dashboard Cite

Pediatric acute and chronic pain experiences involve the interaction of physiological, psychological, behavioural, developmental, pharmacological and situational factors. In the acute perioperative pain setting preventative multimodal analgesia is required to provide comfort and minimise the potential for "wind-up" and central sensitisation. When pain is recurrent, ongoing or chronic some children embark on a downward spiral of decreased physical, psychological and social functioning. The multidisciplinary team management approach is a well-established standard of care for children with complex chronic pain. Intravenous lidocaine has peripheral and central mediated analgesic, anti-inflammatory and anti-hyperalgesic properties. Intravenous lidocaine infusion therapy (IVLT) has been shown to be effective in the management of acute and chronic pain in adults. This chapter will present the rational for IVLT in pediatric pain management with emphasis on preventative multimodal therapy in acute pain and the multidisciplinary treatment approach in chronic pain. Large multi-centre randomised controlled trials are required to provide the evidence-base to confirm that IVLT is indeed an effective and safe treatment option in acute preventative multimodal analgesia and as an adjunct in the multidisciplinary care of chronic pain in the pediatric population. Keywords

show abstract

“…A administração de lidocaína por via venosa raramente produz analgesia que persiste além do tempo de infusão 43 45 . Em paciente com dor neuropática, a infusão de lidocaína por via venosa demandou cerca de cinco minutos para atingir analgesia máxima uma vez iniciada (diferença de tempo entre DE50 e DE90 = 5,3 min) 46 .…”

Section: Diferentes Doses Da Lidocaína Por Via Venosaunclassified

Mecanismos envolvidos na analgesia da lidocaína por via venosa

Lauretti¹

2008

Rev. Bras. Anestesiol.

116

View full text Add to dashboard Cite

Rev Bras AnestesiolARTIGO DE REVISÃO 2008; 58: 3: 280-286 REVIEW ARTICLE RESUMO Lauretti GR -Mecanismos Envolvidos na Analgesia da Lidocaína por Via Venosa. JUSTIFICATIVA E OBJETIVOS:A lidocaína é utilizada por via venosa desde a década de 1960 para diversas finalidades. Seu mecanismo de ação multimodal foi o objetivo principal dessa revisão. CONTEÚDO:Foram revisados mecanismos de ação divergentes do clássico bloqueio do canal de Na + , a ação diferencial da lidocaína venosa na sensibilização central, sua ação analgésica e citoprotetora, assim como as diferentes doses da lidocaína utilizadas por via venosa. CONCLUSÕES:A ação analgésica final da lidocaína por via venosa reflete seu aspecto multifatorial de ação. Em relação à sensibilização central, sugere-se uma ação anti-hiperalgésica periférica da lidocaína na dor somática e central na dor neuropática, com resultante bloqueio da hiperexcitabilidade central. A dose por via venosa não deve exceder a concentração plasmática tóxica de 5 µg.mL BACKGROUND AND OBJECTIVES:Intravenous lidocaine has been used for several indications since the decade of 1960. Its multimodal mechanism of action was the objective of this review. CONTENTS:Mechanisms of action that diverge from the classical Na + channel blockade, the differential action of intravenous lidocaine in central sensitization, and the analgesic and cytoprotective actions, as well as the different doses of intravenous lidocaine were reviewed. CONCLUSIONS:The final analgesic action of intravenous lidocaine is a reflection of its multifactorial action. It has been suggested that its central sensitization is secondary to a peripheral anti-hyperalgic action on somatic pain and central on neuropathic pain, which result on the blockade of central hyperexcitability. The intravenous dose should not exceed the toxic plasma concentration of 5 µg.mL -1 ; doses smaller than 5 mg.kg -1 , administered slowly (30 minutes), under monitoring, are considered safe.

show abstract

Systemic administration of local anesthetic agents to relieve neuropathic pain

Abstract: Analysis 2.3. Comparison 2 Subgroup analyses for comparison 01, Outcome 3 By time of outcome measurement (minus Stracke trial

Cited by 148 publications

References 76 publications

Safety of opioid patch initiation in Australian residential aged care

Safety of opioid patch initiation in Australian residential aged care

A Review of Intravenous Lidocaine Infusion Therapy for Paediatric Acute and Chronic Pain Management

Mecanismos envolvidos na analgesia da lidocaína por via venosa

Contact Info

Product

Resources

About